Investor Relations

Company Overview

Supported by a fast-track designation and a positive EOP2 Meeting with the FDA, Oncolytics is focused on obtaining regulatory approval for REOLYSIN® for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing REOLYSIN® through late-stage clinical testing, submission and registration in this indication presents the highest chance of success with the greatest commercial opportunity.

Latest Presentation

Stock Information

Symbol

OTCQX ONCYF

Price

Change

Symbol

TSX ONC

Price

Change

Investor Relations

Michael Moore
Vice President Investor Relations and Corporate Communications
T: (403) 670-7377 Ext. 2
mmoore@oncolytics.ca